Beck W T, Kim R, Chen M
Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, TN 38101.
Cancer Chemother Pharmacol. 1994;34 Suppl:S14-8. doi: 10.1007/BF00684858.
We review herein current work on the cytotoxic and cellular actions of two classes of inhibitors of DNA topoisomerase II: one represented by etoposide and teniposide, which stabilize DNA-protein complexes, and another represented by merbarone and aclarubicin, which do not stabilize such complexes. We discuss current concepts of protooncogene activation and cell cycle perturbations by some of these inhibitors and summarize recent findings of novel actions of the latter compounds in tumor cells that express a mutant topoisomerase II.
我们在此回顾了关于两类DNA拓扑异构酶II抑制剂的细胞毒性和细胞作用的当前研究工作:一类以依托泊苷和替尼泊苷为代表,它们可稳定DNA-蛋白质复合物;另一类以美拉酮和阿柔比星为代表,它们不会稳定此类复合物。我们讨论了其中一些抑制剂对原癌基因激活和细胞周期扰动的当前概念,并总结了后一类化合物在表达突变型拓扑异构酶II的肿瘤细胞中的新作用的最新发现。